BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
Autolus Therapeutics (NASDAQ:AUTL) stock has reached a 52-week low, touching down at $1.67, marking a 75% decline from its 52-week high of $6.62. According to InvestingPro analysis, the company currently appears undervalued, despite holding more cash than debt on its balance sheet. This new low comes as a stark contrast to the previous year’s performance, with the stock experiencing a significant downturn of -70.4% over the past year. Investors are closely monitoring Autolus as it navigates through the biopharmaceutical sector’s volatile landscape, which has been marked by rapid changes and intense competition. The company’s journey to this 52-week low reflects broader industry trends and investor sentiment, as it strives to regain momentum and improve its market position. For a deeper understanding of AUTL’s potential, InvestingPro subscribers can access 12 additional key insights and a comprehensive Pro Research Report, part of the analysis available for 1,400+ US stocks.
In other recent news, Autolus Therapeutics reported a net loss of $220.7 million for the fourth quarter of 2024, an increase from the previous year’s $208.4 million loss. Despite this, the company significantly boosted its cash reserves to $588 million, primarily due to a $600 million collaboration with BioNTech (NASDAQ:BNTX) and equity financing. Autolus is actively expanding its market presence, with 33 U.S. treatment centers authorized to administer its Aucatzyl therapy, exceeding the initial goal of 30 centers. Mizuho (NYSE:MFG) Securities maintained an Outperform rating for Autolus with a $12 price target, while Truist Securities reaffirmed a Buy rating with an $11 price target, both citing strong demand for Aucatzyl.
The company is also preparing for regulatory decisions in the UK and Europe for its therapy Aucatzyl, with expectations set for the second half of 2025. Autolus plans to expand to 60 centers by the end of 2025, aiming to cover a larger portion of the U.S. patient population. Additionally, Autolus is anticipating key data presentations, including initial pediatric data and updates on systemic lupus erythematosus from its CARLYSLE trial, expected to be shared at an R&D event in April 2025. Analyst firms like Truist Securities highlighted the importance of these upcoming data presentations, which could further boost investor interest in Autolus’s therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.